Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm
A phased tariff structure has been outlined for generic pharmaceutical imports into the US, providing a two-year duty-free window before escalating rates apply
After the grace period, an interim tariff of 100% is set to apply for a further year, before doubling to 200%
Indian pharmaceutical exporters, who supply a large share of the generic medicines consumed in the US, have been assessed as the most exposed globally to this schedule
The move follows an earlier April 2026 action that placed a 100% tariff on patented (branded) drugs and pharmaceutical ingredients under a separate order, from which generics and biosimilars were exempted at that time
Some Indian pharmaceutical companies already operate manufacturing facilities in the US, which analysts note could provide relative insulation once the new schedule takes effect
Section 232 of the US Trade Expansion Act, 1962 — National Security Tariffs
Section 232 authorizes the US President to "adjust" imports — via tariffs, quotas, or license fees — once the Department of Commerce determines that a category of imports threatens to impair national security. It is a unilateral executive tool, distinct from ordinary trade-remedy statutes that require a finding of unfair trade practice.
Key Details
- A Section 232 investigation into pharmaceuticals and active pharmaceutical ingredients (APIs) was initiated by the US Secretary of Commerce on April 1, 2025
- An executive order imposing a 100% tariff on patented pharmaceuticals and associated APIs was issued on April 2, 2026, citing import dependence as a national-security risk — approximately 53% of patented drugs and 85% of patented APIs distributed in the US were found to be foreign-produced
- Section 232 was first used by the same administration for steel and aluminium tariffs in 2018; a 2022 WTO dispute panel found those tariffs violated WTO rules and were not justified under the security exception
- Distinct from Section 301 of the Trade Act, 1974, which authorizes unilateral retaliatory tariffs against "unfair trade practices" (the basis of the 2018-19 US-China tariff dispute) — Section 232 instead rests on a national-security rationale
The phased generic-drug tariff schedule extends the same Section 232 legal architecture used for patented drugs in April 2026 into the generics segment, where India holds the largest global supply share.
GATT Article XXI — The "National Security Exception" in WTO Law
Article XXI of GATT 1994 permits WTO members to deviate from their trade obligations, including the Most Favoured Nation (MFN) commitment under GATT Article I, when "essential security interests" are at stake. It was historically treated as self-judging by the invoking state but has increasingly come under WTO panel scrutiny.
Key Details
- A 2022 WTO panel ruled that the 2018 Section 232 steel and aluminium tariffs breached WTO rules and were not a valid invocation of the security exception
- Under normal WTO rules, MFN treatment (GATT Article I) requires a member to extend the same tariff terms to all other WTO members, absent a recognized exception or free trade agreement
- India has been a WTO member since 1995 (as a founding member, succeeding its GATT 1947 membership) and has pursued WTO disputes over earlier US Section 232 measures affecting Indian steel and aluminium exports
Framing the pharmaceutical tariffs as a national-security matter, rather than an ordinary trade remedy, allows the US to bypass its standard MFN obligations — a legal strategy that shapes how India can contest the measure at the WTO.
India's Pharmaceutical Export Profile
India is the world's largest supplier of generic medicines by volume, sometimes described as the "pharmacy of the world," with the US as its single largest export destination for pharmaceuticals.
Key Details
- Indian companies supply an estimated 40% of generic drugs used in the US, according to the US Food and Drug Administration
- India's total pharmaceutical exports crossed US $30 billion, per the Commerce Secretary; exports to the US alone were approximately US $8.7-9.7 billion in FY2024-25, of which over 95% were generic drugs [figures vary slightly by source]
- Nearly 35% of India's total pharmaceutical exports are destined for the US market
- The sector is tracked by Pharmexcil (Pharmaceuticals Export Promotion Council of India, under the Ministry of Commerce and Industry) and represented industry-wide by the Indian Pharmaceutical Alliance (IPA)
Because the US absorbs over a third of India's pharma exports and India supplies roughly 40% of US generic drug volumes, the new tariff schedule directly affects the export economics of India's largest listed drugmakers.
- Section 232 pharmaceutical investigation initiated: April 1, 2025
- Executive order imposing 100% tariff on patented drugs/APIs: April 2, 2026 (generics and biosimilars exempted at that time)
- Import-dependence figures cited for the national-security finding: ~53% of patented drugs, ~85% of patented APIs distributed in the US sourced from abroad
- Generic drug tariff schedule: duty-free for two years, then 100% for one year, then 200%
- India's pharma exports to the US: approximately US $8.7-9.7 billion (FY2024-25), about 35% of India's total pharma exports
- Indian share of US generic drug supply: approximately 40% (US FDA data)
- India's total pharmaceutical exports: over US $30 billion